Back to News
Market Impact: 0.35
Pfizer's ELREXFIO Meets Phase 3 Endpoint; Median PFS Not Yet Reached; Stock Down
Source: Nasdaq
Healthcare & Biotech
Pfizer announced positive topline results from the Phase 3 MagnetisMM-32 study of ELREXFIO (elranatamab) monotherapy in adults with relapsed or refractory multiple myeloma previously treated with anti-CD38 therapy. The available article text provides no efficacy figures or further trial details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
PFE0.75
More News
- Artiva halts AlloNK development, cuts 94% of workforce
- Universal Health Services falls 3% on legal settlement concerns
- Midterm elections: How affordability and the economy could impact voters
- adar1 capital management buys $53,691 of NextCure stock
- Zura Bio shares jump on Wedbush buy call ahead of trial data
- Why is Artiva Biotherapeutics stock collapsing today?